Abstract-Estrogen regulation of myocardial chymase and chymase effects on cardiac remodeling are unknown. To test the hypothesis that estrogen prevents pressure overload-induced adverse cardiac remodeling by inhibiting mast cell (MC) chymase release, transverse aortic constriction or sham surgery was performed in 7-week-old intact and ovariectomized (OVX) rats. Three days before creating the constriction, additional groups of OVX rats began receiving 17β-estradiol, a chymase inhibitor, or a MC stabilizer. Left ventricular function, cardiomyocyte size, collagen volume fraction, MC density and degranulation, and myocardial and plasma chymase levels were assessed 18 days postsurgery. Aortic constriction resulted in ventricular hypertrophy in intact and OVX groups, whereas collagen volume fraction was increased only in OVX rats. Chymase protein content was increased by aortic constriction in the intact and OVX groups, with the magnitude of the increase being greater in OVX rats. MC density and degranulation, plasma chymase levels, and myocardial active transforming growth factor-β1 levels were increased by aortic constriction only in OVX rats. Estrogen replacement markedly attenuated the constriction-increased myocardial chymase, MC density and degranulation, plasma chymase, and myocardial active transforming growth factor-β1, as well as prevented ventricular hypertrophy and increased collagen volume fraction. Chymostatin attenuated the aortic constriction-induced ventricular hypertrophy and collagen volume fraction in the OVX rats similar to that achieved by estrogen replacement. Nedocromil yielded similar effects, except for the reduction of chymase content. We conclude that the estrogen-inhibited release of MC chymase is responsible for the cardioprotection against transverse aortic constriction-induced adverse cardiac remodeling. 
T he loss of cardioprotection in postmenopausal women represents a significant health issue that is in need of further research to delineate the responsible mechanisms. To this end, we have reported gender differences in the pattern of global myocardial remodeling in response to a sustained cardiac volume overload and demonstrated the protection of estrogen (E2) against volume overload-induced adverse cardiac remodeling. [1] [2] [3] [4] Others have reported similar sex remodeling differences in mice with sustained pressure overload secondary to transverse aortic constriction (TAC). 5 We also found the cardiac mast cell (MC) to be pivotal in initiating the adverse myocardial remodeling that leads to ventricular decompensation in male and ovariectomized (OVX) rats but not in intact (Int) premenopausal female rats. [6] [7] [8] [9] Furthermore, we demonstrated that supplemental E2 administered to male and OVX rats was able to attenuate volume overload-induced adverse cardiac remodeling by its ability to prevent the increase in cardiac MC density and degranulation. 10, 11 Chymase, which is stored in a macromolecular complex in MC cytoplasmic secretory granules and is released after MC activation, plays a crucial role in cardiovascular diseases [12] [13] [14] [15] via its ability to form angiotensin II, activate transforming growth factor (TGF)-β1, IL-1β, and endothelin-1, and degrade the extracellular matrix, as well as its involvement in lipid metabolism. [16] [17] [18] [19] [20] [21] Recently, it has been reported that myocardial fibrosis was decreased in hypertensive rats after a reduction in chymase activity. 22 However, with the exception of a recent study that suggested an association of E2 with chymase in renin-overexpressing mRen2. Lewis female rats, 23 little is known regarding E2's ability to regulate cardiac MC chymase and its association with cardiac remodeling. Accordingly, the purpose of this study was to test the hypothesis that E2 prevents the adverse cardiac remodeling induced by pressure overload by inhibiting cardiac MC chymase release.
Results

Ovarian Hormones Prevented TAC-Induced Adverse LV Remodeling
There were no significant differences in body weight between the Int and OVX rats before TAC surgery. Also, as can be seen in Figure 1A and 1B, ovariectomy did not result in a significant change in the left ventricle (LV)/tibia length (TL) ratio and myocyte cross-sectional area (CSA), respectively. However, it did cause a significant increase in LV interstitial collagen volume fraction (CVF; Figure 1C ) compared with the Int-sham (Int-Sh) rats (2.36±0.12% versus 1.08±0.12%; Figure 1D ). LV hypertrophy occurred in both TAC groups as evidenced by significant increases in LV/TL, myocyte CSA ( Figure 1A and 1B), and LV posterior wall thickness ( Figure  S1C in the online-only Data Supplement), with the increases in the OVX-TAC group being greater than those in the Int-TAC group. LV CVF also significantly increased after 18 days of TAC in the OVX-TAC group (35% increase versus OVX-Sh). In contrast, there was no increase in CVF in the Int-TAC rats relative to the Int-Sh rats ( Figure 1C and 1D) . LV internal diameter, ejection fraction, and fractional shortening, as determined by echocardiography ( Figure S1C ), and lung weight/TL ( Figure S2A ) were similar in the 4 groups, indicating that LV function remained compensated in both TAC groups.
Ovarian Hormones Inhibited TAC-Induced Myocardial MC Chymase Synthesis and Release
LV tissue chymase protein content for the 4 groups, as determined by Western blot (Figure 2A ), is provided in Figure 2B . Also, the plasma chymase levels for the study groups, which are assumed to include the chymase released from myocardial cells, are shown in Figure 2C . As can be seen, ovariectomy had no effect on myocardial chymase protein content and plasma chymase levels compared with the Int-Sh group. However, myocardial chymase protein content was significantly increased in both the Int-TAC and OVX-TAC groups, with the magnitude of the increase being greater in the OVX-TAC group ( Figure 2B ), whereas the plasma chymase level was significantly increased only in the OVX-TAC group ( Figure 2C ).
Chymase is known to be primarily synthesized and stored in MCs. This is demonstrated in Figure 2D , where LV tissue immunostained with a chymase antibody revealed it to be localized in MCs and secreted MC granules. Accordingly, the TAC-induced elevation in tissue chymase protein levels would be indicative of a greater MC chymase synthesis rate, a greater MC density or both, whereas the increase in the plasma chymase level in the OVX-TAC group would reflect enhanced MC degranulation. As depicted in Figure 2E , MC density was increased only in the OVX-TAC group. Thus, although chymase production was elevated in response to TAC in both the Int and OVX groups, the additional increment in the OVX-TAC group ( Figure 2B ) was likely caused by the greater MC density. An estimate of MC degranulation indicated that it was significantly greater in the OVX-TAC group (74.5±1.4%) compared with the other groups (Int-Sh, 62.8%±2.6%; OVX-Sh, 63.2%±1.5%; and Int-TAC, 61.0%±2.4%), which in all likelihood contributed to the plasma chymase levels seen in all 4 groups ( Figure 2C ).
Estrogen Inhibited TAC-Induced Myocardial MC Chymase Synthesis and Release and Prevented Adverse LV Remodeling
The above results clearly reflect the cardioprotective role of ovarian hormones to the adverse myocardial remodeling associated with TAC. Accordingly, estrogen replacement experiments in OVX rats with TAC were performed. Estrogen replacement significantly prevented the TAC-induced increases in LV/TL, myocyte CSA, LV CVF ( Figure 3A-3D) , and systolic and diastolic LV posterior wall thickness ( Figure  S3C ). Estrogen also prevented the TAC-induced increases in tissue chymase protein content ( Figure 4A and 4B) and plasma chymase level ( Figure 4C ). Also shown in Figures 3 and 4 
Chymase Activated TGF-β1
Activated TGF-β1 is known to stimulate collagen synthesis in fibroblast and myofibroblasts. Accordingly, we determined its myocardial levels in the 4 study groups and also the effect of supplementary estrogen, nedocromil, and chymostatin on these levels in OVX-TAC rats. Depicted in Figure 5A and 5B are the 
Discussion
Accumulating evidence has demonstrated the ability of estrogen to markedly attenuate or prevent maladaptive remodeling in response to sustained abnormal elevations in myocardial stress. [2] [3] [4] [5] 24 Cardiac MCs play a pivotal role in adverse remodeling, which is countered by estrogen's ability to induce protective, phenotypic MC changes. [9] [10] [11] 25 Given that myocardial chymase is primarily produced and localized in cardiac MCs and that decreased myocardial fibrosis was reported after a reduction in chymase activity in hypertensive rats, 22 we hypothesized that estrogen prevents adverse myocardial remodeling secondary to a sustained cardiac pressure overload via its ability to diminish the MC synthesis of chymase and attenuate MC degranulation. To this end, intact female and OVX rats were subjected to sham or TAC surgery, and the myocardial remodeling, chymase, and active TGF-β1 levels, as well as MC responses, at 18 days postsurgery compared. The significant finding is that supplemental estrogen, prevention of MC activation, and inhibition of chymase activity are capable of attenuating TAC-induced myocardial remodeling.
Because chymase has been known to exert its actions after it is released into the interstitium, 16, 26 it is necessary to measure extracellular chymase activity to assess its influence on cardiac remodeling. In view of the fact that chymase is activated and stored in MC secretory granules, assessing chymase activity in tissue homogenates will not reflect extracellular chymase activity in the heart. 27 Furthermore, recent reports have indicated that chymase is also present within cardiomyocytes, where it can promote angiotensin II formation. 28, 29 Therefore, to determine the ability of estrogen to regulate myocardial chymase, chymase synthesis and release were assessed by measuring myocardial chymase protein content, plasma chymase levels, and cardiac MC degranulation. The fact that OVX did not have an effect on myocardial chymase synthesis, plasma chymase levels, and MC density and degranulation indicated ovarian hormones did not influence synthesis and release of chymase under basal condition. Myocardial chymase synthesis was increased by TAC in both intact and OVX rats with the magnitude of the increase being greatest in the OVX rats. In contrast, chymase release, as reflected by increased plasma chymase levels and MC degranulation, was elevated by TAC only in the OVX rats. Interestingly, the TAC-induced increase in the synthesis of myocardial chymase paralleled that of LV hypertrophy, and the TAC-induced increase in the release of chymase occurred concomitantly with the enhanced collagen deposition. Estrogen replacement markedly attenuated the TAC-induced increase in myocardial chymase synthesis and release and prevented LV hypertrophy and elevations in collagen deposition in the OVX rats. These results demonstrated that estrogen inhibited TACinduced myocardial chymase synthesis and release and prevented TAC-induced adverse cardiac remodeling.
Previous studies reported chymase activity to be increased in the human atherosclerotic aorta and infarcted hearts 14, 15 and that chymase inhibition suppressed cardiac fibrosis in animal models of myocardial infarction, cardiomyopathy, and tachycardiainduced heart failure. 27, [30] [31] [32] In the present study, the increases in myocardial chymase synthesis and release were found to correlate with TAC-induced LV remodeling. To establish a causal relationship between myocardial chymase and TAC-induced adverse cardiac remodeling, chymostatin was administrated to the OVX-TAC rats. Chymostatin markedly attenuated the TACinduced LV hypertrophy and collagen deposition, indicating myocardial chymase as being responsible for the TAC-induced adverse cardiac remodeling. Moreover, myocardial active TGF-β1 levels were also reduced by chymostatin, suggesting that activation of TGF-β1 is one of the pathways by which chymase promotes cardiomyocyte hypertrophy and collagen deposition. This was further supported by the observations that the TAC-induced increases in active TGF-β1 levels were also attenuated secondary to the estrogen-and nedocromil-induced reductions in chymase release. In addition to chymase activating TGF-β1, other actions of chymase include the conversion of angiotensin I to angiotensin II. 16 Angiotensin II may contribute to the TAC-induced adverse cardiac remodeling either indirectly by stimulating the production of latent TGF-β1 33 or directly by stimulating fibroblast collagen synthesis and myocyte hypertrophy. The measurement of active TGF-β1 should reflect, if any, the contribution of angiotensin II to the latent TGF-β1 pool. However, the direct contribution of angiotensin II to TAC-induced fibrosis and hypertrophy in this study, if any, was not assessed.
The fact that chymase is primarily synthesized and released from MCs was further evidenced by the immunohistochemistry staining showing chymase to be localized in MCs and the externalized MC granules. As a result of elevated myocardial stress secondary to sustained pressure or volume overload or injury, a variety of factors, such as reactive oxygen species and endothelin-1, are released that have the potential to activate cardiac MCs. 34 On activation, cardiac MCs release chymase and numerous other substances that may directly or indirectly influence cardiac fibroblasts, endothelial cells, smooth muscle cells, and myocyte function. Specific to this study, TACstimulated myocardial chymase release was found to correlate with excessive collagen deposition. Furthermore, nedocromil, by preventing MC degranulation, markedly reduced myocardial chymase release and significantly attenuated LV hypertrophy and collagen deposition similar to that achieved by estrogen replacement. The stimulus for the TAC-induced increase in myocardial chymase synthesis, which was not prevented by nedocromil, remains to be determined. Nevertheless, the nedocromil results indicate that MC stabilization could be used as an alternative strategy to that of estrogen replacement therapy or chymase inhibition for the prevention of pressure overload-induced adverse cardiac remodeling.
There is the additional observation herein that OVX resulted in increased LV fibrillar collagen deposition in the absence of changes in myocardial chymase synthesis, MC chymase release, active TGF-β1 levels, and LV hypertrophy. This finding indicates that ovarian hormones are involved in the maintenance of a reduced basal myocardial fibrillar collagen concentration. The fact that 17β-estradiol, its metabolites, and progesterone have been reported to directly inhibit cardiac fibroblast growth and collagen synthesis 35 represents a possible mechanism.
We conclude that the estrogen-inhibited release of myocardial MC chymase is responsible for the cardioprotection against TAC-induced adverse cardiac remodeling in intact females.
Potential Limitations
Although the results clearly indicate that estrogen attenuates TAC-induced fibrosis and myocyte hypertrophy, it remains unknown if the continued use of chymostatin, MC stabilizing drug, or supplementary estrogen would prevent or retard LV dysfunction from occurring. However, previous studies have demonstrated that inhibition of chymase by Qiliqingxin, 22 a specific traditional Chinese drug, and the chymase inhibitors CI-B 27 and SUNC8257 32 reduced myocardial fibrosis and thus attenuated LV dysfunction in spontaneously hypertensive rats, myocardial infarction, and tachycardia-induced heart failure, respectively. Therefore, one could infer from these reports that our results indicating that chymostatin, estrogen replacement, and MC membrane stabilization markedly attenuated TAC-induced myocardial fibrosis indirectly demonstrate that the inhibition of chymase would effectively retard or prevent LV dysfunction. Also, the study did not examine the effects of chymase on other aspects of TAC-induced cardiac remodeling, such as inflammation and myocyte death. Finally, as mentioned earlier, the direct contribution of chymase-induced increases in myocardial angiotensin II, if any, on TAC-induced fibrosis and hypertrophy was not assessed.
Perspective
As summarized in Figure 6 , the results herein demonstrate that estrogen inhibits cardiac MC chymase release to prevent TAC-induced adverse cardiac remodeling, indicating for the first time that estrogen regulation of the cardiac MC chymase release plays an important role in the cardiac remodeling under pressure overload conditions in female rats. Since accumulating evidence has demonstrated the crucial role of chymase in cardiac remodeling, the present findings increase our understanding as to why the postmenopausal incidence of heart failure is significantly increased. Also, these findings suggest that MC stabilization or chymase inhibition could potentially serve as an alternative to or in combination with estrogen replacement therapy to attenuate the fibrosis and myocyte hypertrophy associated with hypertensive heart disease.
Sources of Funding
This work was supported in part by grants from National Institute of Health to J.S. Janicki: HL-59981, HL-62228, and HL-089483.
Disclosures
None. Figure 6 . A schematic of the mast cell-chymase-transforming growth factor (TGF)-β1 pathway responsible for adverse myocardial remodeling in response to transverse aortic constriction (TAC). In response to TAC, mast cell activators are released from myocardial cells to activate cardiac mast cells. Upon activation, cardiac mast cells release chymase into the interstitium, which then activates TGF-β1. Active TGF-β1 stimulates fibroblast and myofibroblast cells to synthesize and secrete collagen as well as promote cardiomyocyte hypertrophy. Estrogen and nedocromil prevent mast cell chymase release and chymostatin inhibits chymase activity. As a consequence, they prevent the TAC-induced increase in TGF-β1 and the resulting adverse cardiac remodeling. 
